stockportfolio.pro
Stocks / AQST vs CTKB
AQST vs CTKB
Aquestive Therapeutics, Inc. and Cytek Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aquestive Therapeutics, Inc. (AQST) | Cytek Biosciences, Inc. (CTKB) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $44.55M | $201.49M |
| Net income (latest FY) | $-83.78M | $-66.54M |
| Revenue growth (5y CAGR) | -0.6% | 209.5% |
| Net margin | -188.1% | -33.0% |
| Return on equity | 248.9% | -19.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 3 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AQST — free Open CTKB — freeFrequently asked questions
Which is bigger, AQST or CTKB?
Cytek Biosciences, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, AQST or CTKB?
Over the last five fiscal years, Cytek Biosciences, Inc. grew revenue faster — 209.5%/yr versus -0.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.